ImageneBio to Participate in Leerink Global Healthcare Conference
Globenewswire·2026-02-26 13:00
Core Insights - ImageneBio, Inc. is participating in the 2026 Leerink Global Healthcare Conference from March 8-11, 2026, with a fireside chat scheduled for March 10 at 3:00 PM EST [1] - The company is focused on developing therapeutics for immunological, autoimmune, and inflammatory diseases, with its lead program being IMG-007, a nondepleting anti-OX40 monoclonal antibody [1] - Imagene has completed Phase 1b/2a clinical trials for IMG-007 in atopic dermatitis and alopecia areata, and is currently conducting a Phase 2b clinical trial for moderate-to-severe atopic dermatitis [1]